Keytruda
pembrolizumab · PD-1 Checkpoint Inhibitor
Indications & Uses
First-line and adjuvant treatment of melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, microsatellite instability-high (MSI-H) solid tumors, triple-negative breast cancer (TNBC), and cervical cancer.
Contraindications
Known severe hypersensitivity to pembrolizumab or any of the excipients in the formulation.
Side Effects & Warnings
Fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, fever, cough, dyspnea, and immune-mediated adverse reactions including pneumonitis, colitis, hepatitis, and endocrinopathies.
Drug & Dietary Interactions
Concomitant use of systemic corticosteroids or immunosuppressants before starting Keytruda may diminish clinical activity; however, systemic steroids may be used to treat immune-mediated adverse reactions.
Regulatory & Prescribing Information
FDA Approved Biologic (BLA 125514). Full Prescribing Information and Medication Guide available.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.